Differences in Central Line Associated Bloodstream Infections Prior to and During the Pandemic
Investigators looked at potential risk factors as incidence rates changed over time after the introduction of COVID-19 and whether race and other variables affected the potential development of these infections.
From Prescription to Treatment: Decreasing the “Hang-Time” of IV Administration of Antimicrobials
How the development of antimicrobial stewardship programs can be an effective strategy for beginning to reduce this critical timing for patients in ICUs.
Examining Beta-Lactams With Vancomycin for Bloodstream Infections for MRSA
A recent novel study found reduced mortality rates in combining these therapies in patients being treated for this specific bacteremia.
Rapid Diagnostic Testing Decreases Broad Spectrum Antibiotic Use in Bloodstream Infections
A study showed utilizing a PCR-based test can narrow therapy quicker and help in resolving these infections sooner.
Investigational Phage Therapy for Cystic Fibrosis Multidrug Resistant Infections Shows 86.6% Resolution
A small study showed high efficacy for the same strain of Pseudomonas aeruginosa.
What Specialties are Using Live Biotherapeutic Products?
With the FDA approval of 2 of these products, which are indicated for recurrent Clostridioides difficile infection (CDI), a study reviewed which types of clinicians are prescribing them and the protocols in using them.
Changing the Antibiotic Reimbursement Model to Encourage Drug Development Proliferation
Although the current reimbursement model makes it difficult for pharmaceutical companies to recoup their investments, a subscription model like the prospective congressional bill, the Pasteur Act, may help change that paradigm. In addition, there are international measures being carried out that may bring about changes.
Melinta Therapeutics Partnering with Venatorx Pharmaceuticals on Commercializing Antibiotic
The companies announced a licensing agreement on cefepime-taniborbactam.
With C Diff Month Set to Begin, the Peggy Lillis Foundation Will Host its 14th Annual Gala
The patient advocacy organization has events in place and is ready to launch its annual C diff awareness campaign.
Adding a Specimen Type to PCR Testing Demonstrates an Increase in RSV Diagnosis
A new study that went beyond the current standard of testing for the respiratory virus resulted in greater incidence rates and a truer accounting of case loads.
Time-to-Treat Proves to be Vital in Severely Ill Patients With Gram-Negative Infections
A clinician discusses the ongoing challenges presented with critically ill patients and the timing and scope of antibiotic prescribing practices.
Why is There Limited Use of Novel, Gram-Negative Antibiotics?
A study presented at IDWeek details some of the shortfalls in utilization.
Novel Intranasal COVID-19 Vaccine Induces Humoral and Cellular Immunity
Codagenix is reporting data at this year’s IDWeek for its live-attenuated vaccine candidate, CoviLiv.
Disparities in FMT for Recurrent Clostridioides difficile
Social determinants such as housing and transportation were strong predictors of patients receiving fecal microbiota transplants (FMT).
The Perils of Medical Tourism: Investigating Fungal Meningitis
Earlier this year, cases of fungal meningitis were discovered at 2 surgical clinics in Matamoros, Mexico. The CDC offers an update on this deadly outbreak.
How AI Can Improve Response Time to Potential Infectious Disease Outbreaks
Toronto, Canada-based Bluedot offers surveillance tracking information to identify trends for viruses and syndromes efficiently to aid public health officials and other key stakeholders to assess situations and make decisions around this data.
Moving AMR to the Forefront of Public Health Preparedness
The subject is one where it does not garner the attention of other serious health topics, but key stakeholders say it should.
Living With C diff: Juggling a Newborn, a Surprising Diagnosis, and a Difficult Year
In our continuing series with members of the Peggy Lillis Foundation, here is an opportunity to hear about people’s experiences, lessons learned, and the new treatments that can lead to hope and not the hopelessness people have been living with during their ordeals.
What We Lost: Public Trust in the Medical Information Discourse Over the Pandemic
Misinformation created unnecessary hospitalizations and mortality and demonstrated the chasm in public health communication.
Insurance Loophole Causes Increased Financial Burden for Those With Chronic Conditions
Alyssa Dykstra is experiencing a drastic increase in paying for her medication for autoimmune arthritis. Insurers are utilizing a loophole provided by the federal government to allow them to disallow coupons, thus raising prescription costs for patients.
Counseling Families on Nirsevimab
With the FDA approval of nirsevimab-alip (Beyfortus), which is indicated for prevention of respiratory syncytial virus (RSV) in infants, clinicians will need to have important conversations with families around this monoclonal antibody, beginning this fall.
Preventing RSV in the Most Vulnerable Population
A clinician offers a glimpse of what it is like to treat infants with respiratory syncytial virus (RSV). And with the recent FDA approval of nirsevimab, how that will likely benefit families and the youngest population.
Long-Acting HIV Injectable Preferable to Daily Oral Regimen
A new study being presented at the ongoing IAS conference showed that people with HIV found the injectable therapy, Cabotegravir plus long-acting Rilpivirine (Cabenuva) is more conducive to today’s lifestyles, reduced stigma, and improved adherence.
World AMR Congress: An Opportunity to Discuss Therapies, Governmental Affairs and Advocacy
This conference is addressing antimicrobial resistance (AMR) from different perspectives and look at strategies to reduce this global health problem.
Harnessing Recombinant Human Polyclonal Antibodies for Potential HBV Treatment, Cure
A company is developing a platform to enable engineering of the first recombinant human polyclonal antibody therapies with the goal of creating a functional cure for hepatitis b (HBV).
Investigational C diff Antibody Takes Novel Mechanism of Action Approach
Lumen Bioscience's C diff therapy, LMN-201, combines four therapeutic proteins that act synergistically to neutralize both the C difficile bacterium and the toxin that causes its virulence directly in the patient’s gastrointestinal tract.
Deconstructing Long-Held Antibiotic Prescribing Myths
Although the literature and science may change, hanging onto beliefs about therapeutics is a tradition passed down from instructors to learners. A change in this paradigm may be warranted.
EU11: What you Need to Know About Vaccine Protection, How it Presents, and Clinical Considerations
This variant, which is an ancestor of Omicron, is an emerging variant that is being seen most frequently in Utah, California, and New York State.
Free, Open Source Tool Harnesses EHR Data to Assess, Improve Antibiotic Prescribing
The Outpatient Automated Stewardship Information System (OASIS) is a platform that allows clinicians the ability to improve their prescribing practices in hopes of delivering a more judicious approach and moving towards stewardship.
National HIV Testing Day: Empowering Everyone to Know Their Status and End the Stigma
HIV testing is for everyone, explains Dr. Uri Belkind, regardless of sexual orientation, race, or gender.
2 Commerce Drive Cranbury, NJ 08512